Mesenteric vein thrombosis.

  title={Mesenteric vein thrombosis.},
  author={Giuseppe Famularo and Giovanni Minisola and Claudio De Simone},
  journal={Annals of emergency medicine},
  volume={51 5},
To the Editor: In the November 2007 issue of Annals of Emergency Medicine, Hugon and colleagues appropriately cite a wide range of hereditary and acquired hypercoagulable disorders as an inherent and often underdiagnosed cause of portal and mesenteric thrombosis; however, no mention of hyperhomocysteinemia is made. We have recently observed two patients with a severe thrombosis in the portal and mesenteric districts in whom elevated blood levels of homocysteine were found at the time thrombosis… Expand
Combined Pharmacomechanical Thrombolysis of Complete Portomesenteric Thrombosis in a Liver Transplant Recipient
This is the first case in which the Trellis pharmacomechanical thrombolysis device was used successfully to treat complete acute thrombosis of the entire superior mesenteric vein and the entire portal vein with extension into all segmental intrahepatic portal branches in a young adult after liver transplantation. Expand
JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis.
JAK2 mutation is strongly associated with SVT, and routine screening of JAK1 mutation appears to be indicated in these patients, but whether screening for the JAK2V617F mutation in VTE patients is justified remains unclear. Expand


Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management.
  • J. Briere
  • Medicine
  • Seminars in thrombosis and hemostasis
  • 2006
Owing to the suspected incidence on the prognosis of BCS of an associated MPD, the present watchful-waiting attitude proposed in MPD without obvious hematologic expression may be challenged. Expand
The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis
Determination of the JAK2 V617F mutation may contribute to the search for genetic determinants of PMVT and may be useful to recognize patients who should be carefully observed for the subsequent development of overt MPDs. Expand
Risk factors for thrombophilia in extrahepatic portal vein obstruction
The risk for EHPVO is increased in the presence of thrombophilia resulting from the prothrombin G20210A mutation and from the deficiencies of the naturally occurring anticoagulant proteins, but not from factor V Leiden. Expand
Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis
JAK2 V617F is a very reliable and noninvasive molecular marker for CMPD and should be used as a first test for diagnosis and is the major cause of primary EHPVO or BCS. Expand
The JAK 2 V 617 F mutation frequently occurs in patients with portal and mesenteric venous thrombosis
D. COLA IZZO,* L . AMITR ANO, G. L . T I SC IA ,* G . SCENNA, E . GRANDO NE ,* M. A . GUARDASC IONE , V. BR ANCAC CI O and M. MARGAGL IONE§* *Unita di Aterosclerosi e Trombosi, IRCCS Casa SollievoExpand
Acute mesenteric vein thrombosis.